Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc.

Net Product Revenues

Net Product Revenues %Chg

Net Product Revenues Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

License, Contract and Collaboration Reimbursement Revenues

License, Contract and Collaboration Reimbursement Revenues %Chg

License, Contract and Collaboration Reimbursement Revenues Common Size

License Revenues

License Revenues %Chg

License Revenues Common Size

Collaboration Services Revenues

Collaboration Services Revenues %Chg

Collaboration Services Revenues Common Size

Collaboration Revenues

Collaboration Revenues %Chg

Collaboration Revenues Common Size

Cost of Goods Sold

Cost of Goods Sold %Chg

Cost of Goods Sold Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

Selling, General and Administrative

Selling, General and Administrative %Chg

Selling, General and Administrative Common Size

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets %Chg

Impairment of Long-Lived Assets Common Size

Restructuring

Restructuring %Chg

Restructuring Common Size

Total Operating Expenses

Total Operating Expenses %Chg

Total Operating Expenses Common Size

Income from Operations

Income from Operations %Chg

Income from Operations Common Size

Interest Expense and Other, Net

Interest Expense and Other, Net %Chg

Interest Expense and Other, Net Common Size

Interest Income and Other, Net

Interest Income and Other, Net %Chg

Interest Income and Other, Net Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Loss on Extinguishment of Debt

Loss on Extinguishment of Debt %Chg

Loss on Extinguishment of Debt Common Size

Other Expenses, Net

Other Expenses, Net %Chg

Other Expenses, Net Common Size

Total Other Expenses, Net

Total Other Expenses, Net %Chg

Total Other Expenses, Net Common Size

Total Other Income, Net

Total Other Income, Net %Chg

Total Other Income, Net Common Size

Net Income

Net Income %Chg

Net Income Common Size

Income Before Income Taxes

Income Before Income Taxes %Chg

Income Before Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Net Loss per Share, Basic and Diluted

Net Loss per Share, Basic and Diluted %Chg

Net Loss per Share, Basic and Diluted Common Size

Shares Used in Computing Basic and Diluted Net Loss per Share

Shares Used in Computing Basic and Diluted Net Loss per Share %Chg

Shares Used in Computing Basic and Diluted Net Loss per Share Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Consolidated Net Income

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Total Revenues	1,123.7	1,106.3	1,062.4	951.6	878.6	835.7
Total Revenues %Chg	5.8%	16.3%	20.9%	13.9%	13.3%	7.2%
Net Product Revenues
License, Contract and Collaboration Reimbursement Revenues
License Revenues
Collaboration Services Revenues
Collaboration Revenues
Cost of Sales	38.6	37.3	38.9	40.5	32	31.2
Cost of Goods Sold
Gross Profit	1,085.1	1,069	1,023.5	911	846.6	804.4
Gross Profit Margin	96.6%	96.6%	96.3%	95.7%	96.4%	96.3%
Selling, General & Administrative Expenses	272	246.1	246	269.6	273.1	234.2
Selling, General and Administrative
Research & Development Expenses	412.6	471.6	438.8	577.3	466.8	535.7
Research and Development
Other Operating Expenses	—	52	33.3	—	—	—
Impairment of Long-Lived Assets
Restructuring
Operating Profit	400.4	299.3	305.3	64.2	106.7	34.5
Operating Margin	35.6%	27.1%	28.7%	6.7%	12.1%	4.1%
Interest and Investment Income	35.9	40	37.2	44.5	42	26.5
Interest Income
Interest Expense	—	—	—	—	—	—
Interest Expense
Non-Operating Income	0.2	-0.2	0.4	-0.2	0.1	0.4
Interest Expense and Other, Net
Interest Income and Other, Net
Loss on Extinguishment of Debt
Other Expenses, Net
Total Other Expenses, Net
Total Non-Operating Income	36.1	39.8	37.5	44.3	42.1	26.9
Income Before Provision for Income Taxes	436.5	339	342.9	108.6	148.8	61.4
Provision for Income Taxes	91.6	81.7	78.7	22.3	27.5	17.6
Provision for Income Taxes
Consolidated Net Income	344.9	257.3	264.2	86.3	121.3	43.8
Net Income Attributable to Common Shareholders	344.9	257.3	264.2	86.3	121.3	43.8
Basic EPS	1.3	0.9	0.9	0.3	0.4	0.1
Diluted EPS	1.2	0.9	0.9	0.3	0.4	0.1
Basic Weighted Average Shares Outstanding	275.7	285.1	295	312	324.3	322.7
Total Shares Outstanding	270.1	281.7	285.2	302.8	320.3	324
Diluted Weighted Average Shares Outstanding	286.3	292.5	299.8	316.1	326.8	325
EBITDA	427.3	327.9	333	92	133.6	58
Effective Tax Rate	21%	24.1%	22.9%	20.5%	18.5%	28.6%